	Application No.	Application No. Applicant(s)	
Notice of Allowability	10/849,282	MOLDENHAUER, MAX	KINF G
	Examiner	Art Unit	
	San-ming Hui	1617	
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT F of the Office or upon petition by the applicant. See 37 CFR 1.31	pears on the cover sheet was (OR REMAINS) CLOSED in or other appropriate common RIGHTS. This application is	ith the correspondence address In this application. If not included Unication will be mailed in due co	urse. THIS
1. This communication is responsive to			
2. The allowed claim(s) is/are <u>1-9</u> .			
 Acknowledgment is made of a claim for foreign priority up a) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have a linear land land land land land land land land	re been received. re been received in Application	on No	n from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDON! THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file MENT of this application.	e a reply complying with the requi	rements
4. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give	nitted. Note the attached EX ves reason(s) why the oath o	AMINER'S AMENDMENT or NOT r declaration is deficient.	TCE OF
5. CORRECTED DRAWINGS (as "replacement sheets") mu	ist be submitted.		•
(a) including changes required by the Notice of Draftsper		w (PTO-948) attached	
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		· · · · · · · · · · · · · · · · · · ·	
(b) ☐ including changes required by the attached Examiner Paper No./Mail Date	's Amendment / Comment o	r in the Office action of	
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in	1.84(c)) should be written on t the header according to 37 Cl	he drawings in the front (not the baFR 1.121(d).	ick) of
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	osit of BIOLOGICAL MAT FOR THE DEPOSIT OF BI	ERIAL must be submitted. Not DLOGICAL MATERIAL.	e the
Attachment(s)	·	formal Datas t A . # . #	
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 	_	formal Patent Application	,
2. Molice of Dranperson's Patent Drawing Review (P10-946)	o. ☐ interview S Paper No.	ummary (PTO-413), /Mail Date	
Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🔲 Examiner's	Amendment/Comment	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ⊠ Examiner's 9. □ Other	Statement of Reasons for Allowa	ince
			•

Application/Control Number: 10/849,282

Art Unit: 1617

DETAILED ACTION

Applicant's amendments filed July 25, 2007 have been entered.

The examiner would like to summarize the interview took place on July 23, 2007 below:

The teachings of Munayyer patent is discussed, especially in the part of Munayyer's teachings of when propylene glycol was incorporated with mometasone, the anti-inflammatory efficacy is diminished. Since the instant topical formulation of mometasone is for anti-inflammatory use, there will be no motivation to incorporate propylene glycol into such composition containing mometasone.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: As discussed in the Applicant's remarks filed July 25, 2007, one of ordinary skill in the art would not have been motivated to incorporate propylene glycol into the mometasone composition since the anti-inflammatory effect of mometasone will be greatly reduced when propylene glycol is used.

Therefore, the outstanding rejection under 35 USC 103(a) will be withdrawn and the claims directed to the composition as claimed will be in condition of allowance. Furthermore, claims 6-9, the method of treating skin inflammation, will be rejoined with claims 1-5.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably Application/Control Number: 10/849,282

Art Unit: 1617

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Page 3

Statement of Reasons for Allowance."

Claims 1-9 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

San-ming Hul Primary Examiner

Art Unit 1617